Insider Transactions

Insider Transactions

Date Name Title Type Shares Traded Price
Jun 27, 2016 Director, President & CEO Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 96,685 $65.96
Mar 23, 2011 Director Open market or private sale of non-derivative or derivative security 25,900 $66.45
Jan 02, 2020 Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 6,500 $66.80
Mar 12, 2019 Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 5,760 $66.80
Mar 11, 2019 Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 740 $66.80
Sep 24, 2018 Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 7,150 $66.80
Jun 23, 2016 Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 2,150 $66.80
Jun 21, 2016 Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 2,000 $66.80
Jun 06, 2016 Director Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 3,000 $66.80
Mar 23, 2011 Director Open market or private sale of non-derivative or derivative security 4,100 $66.85
Dec 12, 2011 CEO - CSI Open market or private sale of non-derivative or derivative security 1,771 $67.31
Mar 10, 2015 EVP, Sec. & Chief Gov. Officer Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 35,500 $67.65
Dec 22, 2014 EVP, COO & Pres-CooperVision Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 12,500 $67.65
Jul 03, 2014 Director, President and CEO Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 54,000 $67.65
Jun 13, 2013 President, CooperVision, Inc. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 6,696 $67.65
Apr 05, 2013 President, CooperVision, Inc. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 23,304 $67.65
Apr 03, 2013 VP & Corporate Controller Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 20,000 $67.65
Oct 03, 2012 Pres, CEO Cooper Medical, Inc. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 25,000 $67.65
Sep 12, 2012 Pres & CEO - CSI Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 25,000 $67.65
Oct 27, 2005 VP, Investor Relations Grant, award or other acquisition pursuant to Rule 16b-3(d) 10,000 $67.65
Oct 27, 2005 Director, President & CEO Grant, award or other acquisition pursuant to Rule 16b-3(d) 66,000 $67.65
Oct 27, 2005 CFO - CooperVision Grant, award or other acquisition pursuant to Rule 16b-3(d) 30,000 $67.65
Oct 27, 2005 Corporate Controller Grant, award or other acquisition pursuant to Rule 16b-3(d) 20,000 $67.65
Oct 27, 2005 Pres & COO - CVI Grant, award or other acquisition pursuant to Rule 16b-3(d) 49,500 $67.65
Oct 27, 2005 Secretary, Sr. VP, & CAO Grant, award or other acquisition pursuant to Rule 16b-3(d) 36,000 $67.65

* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.